The Indian government amended the Drugs Rules, 1945, to establish a uniform regulatory framework for advanced cell and gene therapies [1].
This move is critical because emerging medical technologies often outpace existing laws. By updating these rules, the government aims to close regulatory gaps that could compromise patient safety or allow unverified treatments to enter the market.
The amendment brings several high-tech medical interventions under the Central Licensing Authority (CLAA) framework [2]. This includes stem cell-derived products, gene therapies, and xenografts [2]. Previously, these advanced therapies operated under fragmented or less stringent oversight, creating inconsistency across the healthcare sector.
A report by The Hindu said the move is aimed at strengthening regulatory oversight of such advanced and emerging medical technologies [1]. The goal is to ensure that these therapies meet specific safety and quality standards before they reach patients.
By integrating these therapies into the existing licensing framework, the government can more effectively monitor the development and distribution of CAR-T cell therapies and other regenerative medicines. This standardization is intended to protect patients from unregulated clinics, while providing a clear legal path for legitimate biotech innovation [1].
The update ensures that the 1945 rules remain relevant in an era of precision medicine—a shift that allows the state to maintain control over biological products that modify genetic material or utilize non-human cells [2].
“The Centre’s move is aimed at strengthening regulatory oversight of such advanced and emerging medical technologies.”
This regulatory shift signals India's intention to transition from a reactive to a proactive stance on biotechnology. By absorbing gene and cell therapies into the CLAA framework, the government is legitimizing these therapies as formal pharmaceuticals rather than experimental procedures. This provides the legal certainty necessary to attract international investment in biotech while mitigating the risks associated with the 'stem cell tourism' and unregulated clinics that have historically operated in the shadows of the 1945 rules.
